A review of hot melt extrusion paired fused deposition modeling three-dimensional printing for developing patient centric dosage forms
1 Analytical Research & Development, Hikma Pharmaceuticals, Columbus, Ohio 43228, USA.
2 Department of Pharmaceutics, Pulla Reddy Institute of Pharmacy, Dundigal 502313, India.
Review Article
GSC Biological and Pharmaceutical Sciences, 2022, 21(02), 065–079.
Article DOI: 10.30574/gscbps.2022.21.2.0428
Publication history:
Received on 01 October 2022; revised on 04 November 2022; accepted on 07 November 2022
Abstract:
In recent years, the demand for developing patient-centric dosage forms is increasing enormously with the increasing patient population. Much research is ongoing exploring various additive manufacturing techniques for developing pharmaceutical medications. Poor solubility of drug substances and underdeveloped manufacturing strategies are majorly affecting the pharmaceutical industry's revenue. Developing intravenous dosage forms for drug substances with poor solubility will affect the revenue of the pharmaceutical industries. Thus, improving solubility remains to be the major prerequisite for the developmental scientist. In addition to improving solubility, establishing a robust manufacturing process with commercial viability is also essential. In recent years hot melt extrusion (HME) has been most widely investigated for developing amorphous solid dispersions (ASDs) over other techniques such as spray drying and KinetisolÒ. The process of HME can be coupled with the fused deposition modeling (FDM) three-dimensional (3D) printing technique which is capable of fabricating on-demand patient-centric dosage forms. A continuous manufacturing line can be established by painting HME and FDM 3D printing processes. The quality of the product can be controlled and monitored by employing suitable process analytical technology (PAT) tools. Though the process of the HME-paired FDM 3D printing process has resulted in various advantages compared to the conventional manufacturing process, still many limitations, such as the limited number of polymers, reproducibility, and stability, need to be addressed.
Keywords:
Hot melt extrusion; Fused deposition modeling; Amorphous solid dispersion; Patient-centric dosage forms; Continuous manufacturing; Process analytical technology
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
